Gilead Sciences shared a post on X:
“Gilead News:
Today, we completed our acquisition of Arcellx, which strengthens our oncology portfolio and the long-term potential of an investigational cell therapy for multiple myeloma.
Other articles about Gilead Sciences on OncoDaily.